OneMedPlace Announces Program Updates for Its 6th Annual “OneMedForum,” Jan. 7-9, 2013, in San Francisco
The 6th Annual OneMedForum will take place concurrently with the JP Morgan Healthcare Conference and will feature over 1,000 attendees and more than 100 emerging growth companies from the biotech and medical device sectors. The conference draws a diverse investor attendee base, including: venture capital, private equity, angel networks, family offices, hedge funds, high-net-worth individuals, international investors, research analysts, and strategic partners.
Read more »Release: Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson’s Disease
Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.
Read more »PDUFA: Dec 21– Alexza Pharmaceuticals Inc.
Alexza Pharmaceuticals Inc. [NASDAQ: ALXA] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval […]
Read more »PDUFA: Dec. 20 — Hemispherx Biopharma
Hemispherx Biopharma [NYSE: HEB] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) concerning the approval status […]
Read more »Earnings Release: 11/25 — China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. [NASDAQ: NKBP] has announced that the company plans to release third quarter 2012 financial results on […]
Read more »Diagnostics: Biomarkers, Gene Patents, and Personalized Medicine in Jeopardy
Fallout from the the US Supreme Court landmark decision to deny two patents to Prometheus Laboratories may complicate the future profitability of the industry. If this is indeed a precedent-setting decision, biomarker patents may now fall under the realm of “law of nature”, cutting off the prospect of exclusive market penetration that once justified the significant research and development onus in the early stages.
Read more »OneMedRadio: DARA BioSciences CEO on Oncology Market Opportunity, Key Catalysts
In Part II of our discussion with DARA Biosciences (NASDAQ: DARA) CEO and Chief Medical Officer Dr. David Drutz, we look into key catalysts for the specialty pharmaceutical company. Dr. Drutz discusses the medical need for the oral-liquid tamoxifen, Soltamox, licensed to DARA by UK-based Rosemont Pharmaceuticals — as well as the market opportunity in developing oncology services.
Read more »Bulls, Bears: The State of Cancer Immunotherapy in the Public Markets
This is Part II of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Read more »